Bezafibrate and fenofibrate in Type II diabetics with hyperlipoproteinaemia

References

• Assmann G. Current laboratory diagnosis of lipid disorders. “Lipoproteins and Coronary Heart Disease”, H. 0 Greten, P. D. Lang, G. 0 Schettler. Witzstrock, Baden-Baden 1980; 29.1. Assmann G. Current laboratory diagnosis of lipid disorders. “Lipoproteins and Coronary Heart Disease”, H. 0 Greten, P. D. Lang, G. 0 Schettler. Witzstrock, Baden-Baden 1980; 29.
   Google Scholar
• Assmann G. 0. “Lipid Metabolism and Atherosclerosis”, 0 0. Schattauer, Stuttgart 1982; 02. Assmann G. 0. “Lipid Metabolism and Atherosclerosis”, 0 0. Schattauer, Stuttgart 1982; 0
   Google Scholar
• Björntorp P., Bergman H., Varnauskas E., Lindholm B. Lipid mobilization in relation to body composition in man. Metabolism 1969; 18: 8403. Björntorp P., Bergman H., Varnauskas E., Lindholm B. Lipid mobilization in relation to body composition in man. Metabolism 1969; 18: 840
   PubMed Web of Science ®Google Scholar
• Boberg J., Carlson L. A., Freyschuss V., Lasers B. W., Wahlqvist M. L. Splanchnic secretion rates of plasma triglycerides and total and splanchnic turnover of plasma free fatty acids in men with normo- and hypertriglyceridaemia. Eur. J. Clin. Invest 1972; 2: 4544. Boberg J., Carlson L. A., Freyschuss V., Lasers B. W., Wahlqvist M. L. Splanchnic secretion rates of plasma triglycerides and total and splanchnic turnover of plasma free fatty acids in men with normo- and hypertriglyceridaemia. Eur. J. Clin. Invest 1972; 2: 454
   PubMed Web of Science ®Google Scholar
• Bradley R. R., Bell G. O. Acute hypothyroidism in severe diabetic ketoacidosis. Diabetes 1971; 36: 3305. Bradley R. R., Bell G. O. Acute hypothyroidism in severe diabetic ketoacidosis. Diabetes 1971; 36: 330
   Google Scholar
• Bruneder N., Klein H. J. Behandlung der Hyperlipoproteinamie bei Diabeti-kern: Vergleich von Bezafibrat, Placebo und “essentiellen” Phospholipiden. Dtsch. Med. Wochenscha 1981; 106: 16536. Bruneder N., Klein H. J. Behandlung der Hyperlipoproteinamie bei Diabeti-kern: Vergleich von Bezafibrat, Placebo und “essentiellen” Phospholipiden. Dtsch. Med. Wochenscha 1981; 106: 1653
   PubMedGoogle Scholar
• Desager J.-P., Hulhoven R., Harvengt C. Uricosic effect of fenofibrate in healthy volunteers. J. Clin. Pharmacol 1980; 20: 5607. Desager J.-P., Hulhoven R., Harvengt C. Uricosic effect of fenofibrate in healthy volunteers. J. Clin. Pharmacol 1980; 20: 560
   PubMed Web of Science ®Google Scholar
• Drouin P., Mejan L., Sauvanet J. P., Pointel J. P., Gay J., Debry Y. Etude de l'action hypolipemiante du procétofene chez des malades porteus d'une HLP du Type IIA au IIB. Gaz. Med. Fr 1976; 83: 38488. Drouin P., Mejan L., Sauvanet J. P., Pointel J. P., Gay J., Debry Y. Etude de l'action hypolipemiante du procétofene chez des malades porteus d'une HLP du Type IIA au IIB. Gaz. Med. Fr 1976; 83: 3848
   Google Scholar
• Goodkin G. Mortality factors in diabetes: 20 year mortality study. J. Occup. Med 1975; 17: 7169. Goodkin G. Mortality factors in diabetes: 20 year mortality study. J. Occup. Med 1975; 17: 716
   PubMedGoogle Scholar
• Kaffarnik H., Schneider J., Schubotz R., Hausmann L., Miihlfellner O., Mühlfellner G. Effect of one year's treatment with bezafibrate on lipids and glucose tolerance in patients with various types of hyperlipoproteinaemia. “Lipoproteins and Ccronary Heart Disease”, H. 0 Greten, P. D. Lang, G. 0 Schettler. Witzstrock, Baden-Baden 1980; 163.10. Kaffarnik H., Schneider J., Schubotz R., Hausmann L., Miihlfellner O., Mühlfellner G. Effect of one year's treatment with bezafibrate on lipids and glucose tolerance in patients with various types of hyperlipoproteinaemia. “Lipoproteins and Ccronary Heart Disease”, H. 0 Greten, P. D. Lang, G. 0 Schettler. Witzstrock, Baden-Baden 1980; 163.
   Google Scholar
• Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med 1971; 74: 111. Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med 1971; 74: 1
   PubMed Web of Science ®Google Scholar
• Olsson A. G. New drug treatments in hyperlipidaemia. “'Atherosclerosis V”, A. M. Gotto, Jr., L. C. Smith, B. 0 Allan. Springer-Verlag, New York, Heidelberg, Berlin 1980; 8612. Olsson A. G. New drug treatments in hyperlipidaemia. “'Atherosclerosis V”, A. M. Gotto, Jr., L. C. Smith, B. 0 Allan. Springer-Verlag, New York, Heidelberg, Berlin 1980; 86
   Google Scholar
• Olsson A. G., Lang P. D. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1978; 31: 42913. Olsson A. G., Lang P. D. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1978; 31: 429
   PubMed Web of Science ®Google Scholar
• Olsson A. G., Rössner S., Walldius G., Carlson L. A., Lang P. D. Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 1977; 27: 27914. Olsson A. G., Rössner S., Walldius G., Carlson L. A., Lang P. D. Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 1977; 27: 279
   PubMed Web of Science ®Google Scholar
• Renold A. E., Acher W. S., Cahil G. H. Diabetes mellitus. “The Metabolic Basis of Inherited Disease”, J. B. Stanbury, J. B. Wyngaarden, D. F. Fredrickson. McGraw Hill, New York 1972; 015. Renold A. E., Acher W. S., Cahil G. H. Diabetes mellitus. “The Metabolic Basis of Inherited Disease”, J. B. Stanbury, J. B. Wyngaarden, D. F. Fredrickson. McGraw Hill, New York 1972; 0
   Google Scholar
• Seidl O., Keller C., Wolfram G. Isoenzymes of alkaline phosphatase during treatment with bezafibrate. “Lipoprotein Metabolism and Therapy of Lipid Disorders”, G. 0 Crepaldi, H. 0 Greten, G. 0 Schettler, G. 0 Baggio. Excerpta Medica, Amsterdam, Oxford, Princeton 1982; 9716. Seidl O., Keller C., Wolfram G. Isoenzymes of alkaline phosphatase during treatment with bezafibrate. “Lipoprotein Metabolism and Therapy of Lipid Disorders”, G. 0 Crepaldi, H. 0 Greten, G. 0 Schettler, G. 0 Baggio. Excerpta Medica, Amsterdam, Oxford, Princeton 1982; 97
   Google Scholar
• Schwandt P., Weisweiler P. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinaemia Type IV. Artery 1980; 7: 46417. Schwandt P., Weisweiler P. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinaemia Type IV. Artery 1980; 7: 464
   PubMedGoogle Scholar
• Schwandt P., Weisweiler P., Drosner M., Janetschek P. Effects of bezafibrate on the composition of very low density lipoproteins in Type IV hyperlipoproteinemia. Atherosclerosis 1982; 42: 24918. Schwandt P., Weisweiler P., Drosner M., Janetschek P. Effects of bezafibrate on the composition of very low density lipoproteins in Type IV hyperlipoproteinemia. Atherosclerosis 1982; 42: 249
   Google Scholar
• Stamler J. Research related to risk factors. Circulation 1979; 60: 157519. Stamler J. Research related to risk factors. Circulation 1979; 60: 1575
   PubMed Web of Science ®Google Scholar
• Steel R. G. D., Torrie J. H. 0. “Principles and Procedures of Statistics”, 0 0. McGraw Hill, New York 1960; 020. Steel R. G. D., Torrie J. H. 0. “Principles and Procedures of Statistics”, 0 0. McGraw Hill, New York 1960; 0
   Google Scholar
• Topping D. L., Mayes P. A. The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochem. J 1972; 126: 29521. Topping D. L., Mayes P. A. The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochem. J 1972; 126: 295
   PubMed Web of Science ®Google Scholar
• Vessby B., Lithell H., Hellsing K., östlund-Lindqvist A.-M., Gustafsson I.-B., Boberg J., Ledermann H. Effects of bezafibrate on the serum lipoprotein lipid and apolipo-protein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis 1980; 37: 25722. Vessby B., Lithell H., Hellsing K., östlund-Lindqvist A.-M., Gustafsson I.-B., Boberg J., Ledermann H. Effects of bezafibrate on the serum lipoprotein lipid and apolipo-protein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis 1980; 37: 257
   PubMed Web of Science ®Google Scholar
• Vogelberg K. H., Gries F. A. Hyperlipopoproteinamie bei Diabetes mellitus. Münch. Med. Wochenschs 1973; 115: 65023. Vogelberg K. H., Gries F. A. Hyperlipopoproteinamie bei Diabetes mellitus. Münch. Med. Wochenschs 1973; 115: 650
   Google Scholar
• Wahl P., Hasslacher Ch., Lang P. D., Vollmar J. Der lipidsenkende Effekt von Bezafibrat bei Patienten mit Diabetes mellitus und Hyperlipidämie. Dtsch. Med. Wochenschr 1978; 103: 123324. Wahl P., Hasslacher Ch., Lang P. D., Vollmar J. Der lipidsenkende Effekt von Bezafibrat bei Patienten mit Diabetes mellitus und Hyperlipidämie. Dtsch. Med. Wochenschr 1978; 103: 1233
   PubMedGoogle Scholar
• Walldius G. Serum triglycerides and fatty acid incorporation into human adipose tissue (FIAT). Acta Med. Scand 1976; 200: 40925. Walldius G. Serum triglycerides and fatty acid incorporation into human adipose tissue (FIAT). Acta Med. Scand 1976; 200: 409
   PubMed Web of Science ®Google Scholar
• Wiklund O., Witztum J. L., Carew T. E., Pittman R. C., Elam R., Steinberg D. Sites of degradation of glucosylated LDL-antibody complexes in rabbits. Clin. Res 1984; 32: 86A26. Wiklund O., Witztum J. L., Carew T. E., Pittman R. C., Elam R., Steinberg D. Sites of degradation of glucosylated LDL-antibody complexes in rabbits. Clin. Res 1984; 32: 86A
   Google Scholar